Derek Duckett
Overview
Explore the profile of Derek Duckett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghosh P, Schmitz M, Pandurangan T, Zeleke S, Chin Chan S, Mosior J, et al.
RSC Chem Biol
. 2024 Oct;
PMID: 39450271
The CDK12 inhibitor SR-4835 promotes the proteasomal degradation of cyclin K, contingent on the presence of CDK12 and the CUL4-RBX1-DDB1 E3 ligase complex. The inhibitor displays molecular glue activity, which...
2.
Gonzalez-Rodriguez M, Troutman S, Bayle S, Lester D, Grove M, Duckett D, et al.
Oncogene
. 2024 Aug;
43(40):2995-3002.
PMID: 39209965
Neurofibromatosis type 2 (NF2) is a rare disorder that causes vestibular schwannomas (VS), meningiomas and ependymomas. To date, there is no FDA approved drug-based treatment for NF2. We have previously...
3.
Morozova A, Chin Chan S, Bayle S, Sun L, Grassie D, Iermolaieva A, et al.
Eur J Med Chem
. 2024 Jan;
266:116101.
PMID: 38232465
The UNC-51-like kinase-1 (ULK1) is one of the central upstream regulators of the autophagy pathway, represents a key target for the development of molecular probes to abrogate autophagy and explore...
4.
Bhutada I, Khambati F, Cheng S, Tiek D, Duckett D, Lawrence H, et al.
Neuro Oncol
. 2023 Aug;
26(1):70-84.
PMID: 37551745
Background: Glioblastoma (GBM) is refractory to current treatment modalities while side effects of treatments result in neurotoxicity and cognitive impairment. Here we test the hypothesis that inhibiting CDK7 or CDK9...
5.
Law V, Chen Z, Vena F, Smalley I, MacAulay R, Evernden B, et al.
Neuro Oncol
. 2022 Feb;
24(10):1673-1686.
PMID: 35213727
Background: Leptomeningeal disease (LMD) occurs as a late complication of several human cancers and has no rationally designed treatment options. A major barrier to developing effective therapies for LMD is...
6.
Law V, Baldwin M, Ramamoorthi G, Kodumudi K, Tran N, Smalley I, et al.
J Vis Exp
. 2021 Feb;
(167).
PMID: 33586709
Leptomeningeal disease (LMD) is an uncommon type of central nervous system (CNS) metastasis to the cerebral spinal fluid (CSF). The most common cancers that cause LMD are breast and lung...
7.
Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman S, et al.
Mol Cancer Ther
. 2020 May;
19(8):1623-1635.
PMID: 32430484
Although gemcitabine is the cornerstone of care for pancreatic ductal adenocarcinoma (PDA), patients lack durable responses and relapse is inevitable. While the underlying mechanisms leading to gemcitabine resistance are likely...
8.
Quereda V, Hou S, Madoux F, Scampavia L, Spicer T, Duckett D
SLAS Discov
. 2018 May;
23(8):842-849.
PMID: 29750582
Glioblastoma (GBM) is the most aggressive primary brain cancer with an average survival time after diagnosis of only 12-14 months, with few (<5%) long-term survivors. A growing body of work...
9.
Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, et al.
Bioorg Med Chem
. 2018 Jan;
26(3):590-602.
PMID: 29289448
Casein kinase 1δ/ε have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series...
10.
Monastyrskyi A, Bayle S, Quereda V, Grant W, Cameron M, Duckett D, et al.
Bioorg Med Chem Lett
. 2017 Dec;
28(3):400-404.
PMID: 29277458
The development of a new series of apoptosis signal-regulating kinase 1 (ASK1) inhibitors is described. Starting from purine, pyrimidine and quinazoline scaffolds identified by high throughput screening, we used tools...